ARKRAY, Inc. Market Share Analysis

• Publication date: October 2012
• Report size: 44 pages

ARKRAY, Inc. Market Share Analysis Summary GlobalData’s new report, “ARKRAY, Inc.. Market Share Analysis” provides in-depth information on ARKRAY, Inc..’s market position in the glucose monitoring devices market. The report also provides data and information on the overall competitive landscape within the glucose monitoring devices market. The report is supplemented with global corporate-level profile ...

ARKRAY, Inc. Market Share Analysis



Summary



GlobalData’s new report, “ARKRAY, Inc.. Market Share Analysis” provides in-depth information on ARKRAY, Inc..’s market position in the glucose monitoring devices market. The report also provides data and information on the overall competitive landscape within the glucose monitoring devices market. The report is supplemented with global corporate-level profile with information on the company’s business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.



Scope


- Global company shares (in Revenues) information for the glucose monitoring devices market.
- ARKRAY, Inc..’s company shares (in Revenues) information for all the key countries the company has presence in – Japan, China, India, Australia, United States, Germany, France, Italy and United Kingdom.
- ARKRAY, Inc..’s company shares (in Revenues) information for the glucose monitoring devices market.
- All the key data-points are for 2011 and cover all the key regions – Asia-Pacific, South and Central America, Middle East and Africa, North America and Europe.
- Global corporate-level profile with information on the company’s business segments, major products and services, competitors, and locations and subsidiaries.



Reasons to buy


- Develop sales and marketing strategies by identifying who-stands-where in the markets, ARKRAY, Inc..’s operates in.
- Plan your competition strategies by identifying the company’s shares in the markets and geographic regions it operates in.
- Design your own inorganic growth and business-collaboration strategies by understanding the financial deals your competitors are involved in.
- Advance your understanding of the competitive landscape and the competitors by leveraging on the data and information provided in the report.
- Support your overall business strategies by leveraging on the key data and information provided in the report, which includes but not limited to ARKRAY, Inc..’s market positions.

In Vitro Diagnostic Industry in China

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
3 Definitions of Markets/Categories Covered 7
3.1 Diabetes Care Devices 7
3.1.1 Glucose Monitoring 7
4 Company Snapshot 8
4.1 Key Information 8
4.2 Company Overview 8
4.3 Business Overview 9
4.4 Major Products and Services 10
4.4.1 Overview 10
5 History 11
6 Competitors 15
7 Competitive Landscape 16
7.1 Diabetes Care Devices (Glucose Monitoring), Global, Market Share (%), 2011 16
7.2 ARKRAY, Inc., Diabetes Care Devices(Glucose Monitoring), by Region, Market Share (2011) 18
7.3 ARKRAY, Inc., Diabetes Care Devices(Glucose Monitoring), by Country, Market Share (2011) 19
8 Key Employees 21
9 Key Employee Biographies 22
10 Company Statement 23
11 Locations And Subsidiaries 24
11.1 Head Office 24
11.2 Other Locations & Subsidiaries 24
12 Financial Deals Landscape 25
12.1 Arkray, Inc., Deals Volume Summary, 2006 to YTD 2012 25
13 Arkray, Inc. Detailed Deal Summary 27
13.1 Partnerships 27
13.1.1 Sysmex Enters Into Co-Development Agreement With ARKRAY 27
13.1.2 ARKRAY Signs Distribution Agreement With Nipro 28
13.1.3 Nicholas Piramal India And ARKRAY Form ARKRAY PIRAMAL Medical 29
13.2 Asset Transactions 30
13.2.1 Merit Medical Systems Completes Acquisition Of Futura Safety Scalpel From Hypoguard USA 30
13.3 Acquisition 31
13.3.1 ARKRAY Acquires 49% Stake In ARKRAY PIRAMAL Medical From Piramal Healthcare 31
13.3.2 ARKRAY Europe Acquires 34% Stake In ELITECH France From The Elitech Group 32
14 Recent Developments 33
14.1 Government and Public Interest 33
14.1.1 Aug 14, 2009: ARKRAY Statement Regarding US FDA's Public Health Notification: Potentially Fatal Errors With GDH-PQQ Glucose Monitoring Technology 33
14.2 Product News 33
14.2.1 Aug 27, 2012: ARKRAY To Launch i-densy IS – 5320 Gene Analyzer 33
14.2.2 Jan 12, 2010: ARKRAY Introduces Assure Platinum Blood Glucose Monitoring System 34
14.2.3 Dec 15, 2009: ARKRAY USA Re-Launches CLIA Waived DiaScreen 50 Urine Chemistry Analyzer 34
14.2.4 Dec 10, 2009: FDA 510(K) Clears ARKRAY's Assure Platinum Auto-Code Blood Glucose Monitoring System 35
14.2.5 Nov 05, 2009: ARKRAY Gets FDA Clearance For Its New GLUCOCARD Vital Blood Glucose Monitoring System 35
14.2.6 Jun 27, 2008: ARKRAY USA Receives FDA (JOBS) Clearance On GLUCOCARD 01 Blood Glucose Monitoring System 36
14.2.7 Dec 19, 2007: Nicholas Piramal Enters Into A Joint Venture With ARKRAY, Inc. Japan, For Marketing Diagnostic Products, Mainly Self-Monitori 36
14.3 Product Approvals 37
14.3.1 Dec 10, 2009: FDA 510(K) Clears ARKRAY's Assure Platinum Auto-Code Blood Glucose Monitoring System 37
14.3.2 Nov 05, 2009: ARKRAY Gets FDA Clearance For Its New GLUCOCARD Vital Blood Glucose Monitoring System 37
14.3.3 Jun 27, 2008: ARKRAY USA Receives FDA (JOBS) Clearance On GLUCOCARD 01 Blood Glucose Monitoring System 38
14.4 Other Significant Developments 38
14.4.1 Jul 01, 2009: ARKRAY Signs Distribution Agreement With NIPRO Medical 38
15 Appendix 39
15.1 Research Methodology 40
15.2 Secondary Research 40
15.3 Primary Research 41
15.4 Models 41
15.5 Forecasts 41
15.6 Expert Panels 42
15.7 GlobalData Consulting 42
15.8 Currency Conversion 43
15.9 Contact Us 44
15.10 Disclaimer 44

List of Tables

Table 1: Arkray, Inc., Key Information, 2011 8
Table 2: Diabetes Care Devices (Glucose Monitoring), Global, Company Share by Revenue ($m), 2011 17
Table 3: ARKRAY, Inc., Diabetes Care Devices (Glucose Monitoring), by Region, Revenue ($m) and Market Share (%), 2011 18
Table 4: ARKRAY, Inc., Diabetes Care Devices (Glucose Monitoring), by Country, Revenue ($m) and Market Share (%), 2011 20
Table 5: Arkray, Inc., Key Employees 21
Table 6: Arkray, Inc., Other Locations 24
Table 7: Arkray, Inc., Subsidiaries 24
Table 8: Arkray, Inc., Deals Volume Summary, 2006 to YTD 2012 25
Table 9: Arkray, Inc., Deals Summary, 2006 to YTD 2012 26
Table 10: Sysmex Enters Into Co-Development Agreement With ARKRAY 27
Table 11: ARKRAY Signs Distribution Agreement With Nipro 28
Table 12: Nicholas Piramal India And ARKRAY Form ARKRAY PIRAMAL Medical 29
Table 13: Merit Medical Systems Completes Acquisition Of Futura Safety Scalpel From Hypoguard USA 30
Table 14: ARKRAY Acquires 49% Stake In ARKRAY PIRAMAL Medical From Piramal Healthcare 31
Table 15: ARKRAY Europe Acquires 34% Stake In ELITECH France From The Elitech Group 32
Table 16: USD to Local Currency, Average Exchange Rate, 2011 43

1.2 List of Figures

Figure 1: Diabetes Care Devices (Glucose Monitoring), Global, Market Share (%), 2011 16
Figure 2: ARKRAY, Inc., Diabetes Care Devices (Glucose Monitoring), by Region, Market Share (%), 2011 18
Figure 3: ARKRAY, Inc., Diabetes Care Devices (Glucose Monitoring), by Country, Market Share (%), 2011 19
Figure 4: Arkray, Inc., Deals Volume Summary, 2006 to YTD 2012 25

Companies mentioned
Terumo Corporation
A. Menarini Industrie Farmaceutiche Riunite Srl
F. Hoffmann-La Roche Ltd.
LifeScan, Inc.
Becton, Dickinson and Company
Bayer HealthCare AG
Abbott Laboratories
Nipro Corporation
Medtronic, Inc.